| AbbVie Inc. (ABBV) |
| Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | Q1-CY2014 | Q4-CY2013 |
| Balance Sheet Date | | 2025-Sep-30 | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2023-Dec-31 | 2023-Sep-30 | 2023-Jun-30 | 2023-Mar-31 | 2022-Dec-31 | 2022-Sep-30 | 2022-Jun-30 | 2022-Mar-31 | 2021-Dec-31 | 2021-Sep-30 | 2021-Jun-30 | 2021-Mar-31 | 2020-Dec-31 | 2020-Sep-30 | 2020-Jun-30 | 2020-Mar-31 | 2019-Dec-31 | 2019-Sep-30 | 2019-Jun-30 | 2019-Mar-31 | 2018-Dec-31 | 2018-Sep-30 | 2018-Jun-30 | 2018-Mar-31 | 2017-Dec-31 | 2017-Sep-30 | 2017-Jun-30 | 2017-Mar-31 | 2016-Dec-31 | 2016-Sep-30 | 2016-Jun-30 | 2016-Mar-31 | 2015-Dec-31 | 2015-Sep-30 | 2015-Jun-30 | 2015-Mar-31 | 2014-Dec-31 | 2014-Sep-30 | 2014-Jun-30 | 2014-Mar-31 | 2013-Dec-31 |
| Fiscal Period | | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q3-FY2023 | Q2-FY2023 | Q1-FY2023 | Q4-FY2022 | Q3-FY2022 | Q2-FY2022 | Q1-FY2022 | Q4-FY2021 | Q3-FY2021 | Q2-FY2021 | Q1-FY2021 | Q4-FY2020 | Q3-FY2020 | Q2-FY2020 | Q1-FY2020 | Q4-FY2019 | Q3-FY2019 | Q2-FY2019 | Q1-FY2019 | Q4-FY2018 | Q3-FY2018 | Q2-FY2018 | Q1-FY2018 | Q4-FY2017 | Q3-FY2017 | Q2-FY2017 | Q1-FY2017 | Q4-FY2016 | Q3-FY2016 | Q2-FY2016 | Q1-FY2016 | Q4-FY2015 | Q3-FY2015 | Q2-FY2015 | Q1-FY2015 | Q4-FY2014 | Q3-FY2014 | Q2-FY2014 | Q1-FY2014 | Q4-FY2013 |
| Price to Sales | 6.80x | 6.86x | 5.62x | 6.45x | 5.58x | 6.28x | 5.50x | 5.91x | 5.04x | 4.77x | 4.24x | 4.97x | 4.92x | 4.11x | 4.73x | 5.05x | 4.26x | 3.45x | 3.70x | 3.81x | 4.13x | 3.81x | 4.01x | 3.31x | 3.94x | 3.41x | 3.29x | 3.64x | 4.23x | 4.45x | 4.75x | 5.07x | 5.48x | 5.19x | | | | | | | | | | | | | | | |
| Price to Book | - | - | - | 260.39x | 94.50x | 57.79x | 44.67x | 40.13x | 26.44x | 21.75x | 18.48x | 21.24x | 16.56x | 14.85x | 18.50x | 17.61x | 15.54x | 14.06x | 15.83x | 13.94x | 14.48x | 10.13x | 9.87x | - | - | - | - | - | - | - | - | 42.29x | 30.33x | 21.19x | | | | | | | | | | | | | | | |
| Price to Earnings | 172.76x | 174.26x | 88.09x | 88.99x | 74.14x | 68.61x | 57.16x | 54.01x | 56.83x | 40.66x | 27.53x | 37.43x | 24.27x | 17.81x | 21.58x | 23.13x | 20.89x | 25.55x | 30.19x | 37.59x | 41.60x | 21.14x | 21.03x | 13.42x | 16.70x | 34.69x | 26.28x | 22.30x | 24.51x | 19.02x | 22.92x | 23.66x | 29.26x | 21.42x | | | | | | | | | | | | | | | |
| Price to Unlevered FCF | 20.61x | 20.79x | 17.98x | 24.03x | 17.62x | 22.31x | 17.03x | 14.68x | 12.41x | 10.64x | 9.59x | 11.99x | 11.78x | 10.84x | 12.20x | 13.01x | 10.89x | 8.79x | 10.16x | 10.74x | 11.28x | 10.09x | 10.28x | 8.31x | 10.25x | 8.66x | 8.42x | 9.02x | 10.84x | 12.01x | 13.59x | 15.10x | 16.39x | | | | | | | | | | | | | | | | |
| Debt to Asset Ratio | | 1.02x | 1.00x | .99x | .98x | .96x | .95x | .95x | .92x | .91x | .90x | .90x | .88x | .89x | .90x | .89x | .89x | .91x | .91x | .91x | .91x | .90x | .90x | 1.08x | 1.09x | 1.14x | 1.15x | 1.14x | 1.14x | 1.04x | 1.05x | .95x | .93x | .90x | .91x | .92x | .93x | .90x | .92x | .91x | .93x | .91x | .90x | .95x | .94x | .84x | .82x | .84x | .85x |
| Current Ratio | | .72x | .74x | .76x | .66x | .65x | .81x | .94x | .87x | .96x | .89x | .96x | .96x | .93x | .84x | .82x | .79x | 1.01x | .91x | .83x | .84x | .95x | .86x | 3.14x | 3.18x | 1.15x | .89x | 1.04x | .98x | 1.20x | .80x | 1.20x | 1.28x | 1.45x | 1.38x | 1.76x | 1.65x | 1.79x | 1.81x | 1.56x | 1.50x | 2.03x | 1.50x | 1.39x | 1.41x | 2.65x | 2.82x | 2.79x | 2.59x |
✓